<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Intrapartum category I, II, and III fetal heart rate tracings: Management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Intrapartum category I, II, and III fetal heart rate tracings: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Intrapartum category I, II, and III fetal heart rate tracings: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George Macones, MD, MSCE</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vincenzo Berghella, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H11183965"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Interpretation of intrapartum electronic fetal heart rate (FHR) tracings has been hampered by interobserver and intraobserver variability, which historically has been high [<a href="#rid1">1-3</a>]. In 2008, the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal-Fetal Medicine (SMFM), and the United States National Institute of Child Health and Human Development (NICHD) convened a workshop to standardize definitions for and interpretation of electronic fetal monitoring (EFM), propose management guidelines, and develop research questions [<a href="#rid4">4,5</a>]. Major outputs from this workshop were clearer standards for FHR interpretation  (<a class="graphic graphic_table graphicRef65859" href="/d/graphic/65859.html" rel="external">table 1A</a>) and a three-tier system for the categorization of intrapartum EFM  (<a class="graphic graphic_table graphicRef57583" href="/d/graphic/57583.html" rel="external">table 1B</a>). This system has been widely adopted in the United States and elsewhere, and is the basis for this topic. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.figo.org%2Fresources&amp;token=oN6rXOmeBLkIpfIsq5mH5aJodyYpLYJLCovWsYaS8xy7w1axErVPb1BxG49%2BRYzF&amp;TOPIC_ID=16663" target="_blank">International Federation of Gynecology and Obstetrics</a> (FIGO2015) [<a href="#rid6">6</a>] and others have published similar guidelines [<a href="#rid7">7-10</a>]. In the FIGO consensus guidelines, for example, FHR tracings are classified as normal, suspicious, or pathological  (<a class="graphic graphic_table graphicRef116405" href="/d/graphic/116405.html" rel="external">table 2</a>) [<a href="#rid6">6</a>].</p><p>A meta-analysis assessing the relationship between the three-tiered classification system during the last 30 to 120 minutes of the FHR tracing and newborn outcomes confirmed previous impressions about the classification system, but was limited by the small number of studies meeting eligibility criteria and the poor quality of the largest study [<a href="#rid11">11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The most common tracing is category II (73 percent versus 27 percent classified as category I and 0.1 percent classified as category III).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The incidence of Apgar score &lt;7 at five minutes is more common with category II and III tracings than category I tracings (1.5 and 14.6 percent, respectively, versus 0.7 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Category III tracings have the highest risks of umbilical artery pH &lt;7.0 and hypoxic ischemic encephalopathy (31 and 19 percent, respectively), while the risks of both are lower and not significantly different for category I and II tracings (pH &lt;7.0: 0.14 and 1.4 percent, respectively; hypoxic ischemic encephalopathy: 0 and 0.8 percent, respectively) .</p><p></p><p>Intrapartum management of category I, II, and III FHR patterns will be discussed here. An overview of issues related to intrapartum FHR assessment is available separately. (See  <a class="medical medical_review" href="/d/html/418.html" rel="external">"Intrapartum fetal heart rate monitoring: Overview"</a>.)</p><p class="headingAnchor" id="H11183972"><span class="h1">CATEGORY I PATTERN: NORMAL</span><span class="headingEndMark"> — </span>This pattern is considered normal because studies have demonstrated absence of fetal metabolic acidemia when the diagnostic criteria for a category I pattern are present [<a href="#rid12">12-15</a>]. </p><p class="headingAnchor" id="H1543790234"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>A category I pattern  (<a class="graphic graphic_waveform graphicRef86064" href="/d/graphic/86064.html" rel="external">waveform 1</a>) is defined by:</p><p class="bulletIndent1"><span class="glyph">●</span>Baseline rate of 110 to 160 beats per minute (bpm)</p><p class="bulletIndent1"><span class="glyph">●</span>Moderate FHR variability (ie, amplitude 6 to 25 bpm)</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of late decelerations</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of variable decelerations</p><p></p><p class="bulletIndent1">Early decelerations and accelerations may be present or absent.</p><p></p><p class="headingAnchor" id="H2358845133"><span class="h2">Management</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intervention</strong> – No resuscitative interventions are warranted since the fetus is presumed to be adequately oxygenated and nonacidemic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Electronic fetal monitoring (EFM) is generally performed continuously even in pregnancies with a category I pattern since the fetal status can change abruptly; however, if the maternal and fetal conditions appear stable, it is reasonable to interrupt monitoring of a category I pattern for up to 30 minutes to facilitate ambulation, bathing, position changes, or other activities for maternal comfort. It is also reasonable to switch to intermittent FHR monitoring in low-risk pregnancies (ie, those without risk factors that increase the risk for a complicated birth) as long as the category I pattern persists: The FHR is checked at least every 30 minutes in the active phase of the first stage of labor and at least every 15 minutes in the second stage [<a href="#rid16">16</a>]. For patients with a category I pattern and pregnancy complications potentially associated with fetal hypoxemia where the risk of developing fetal acidosis is higher, continuous EFM is most practical as the EFM should be reviewed at least every 15 minutes in the first stage of labor and every five minutes during the second stage, based on expert opinion [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/418.html" rel="external">"Intrapartum fetal heart rate monitoring: Overview"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intermittent auscultation can be used in pregnancies that are not at high risk for adverse outcomes. However, intermittent auscultation only identifies changes in baseline rate and cannot measure variability or clearly identify FHR patterns. One reasonable approach to intermittent auscultation is to evaluate and record the FHR every 15 minutes in the active phase of the first stage of labor and every five minutes in the second stage. (See  <a class="medical medical_review" href="/d/html/418.html" rel="external">"Intrapartum fetal heart rate monitoring: Overview", section on 'Frequency and duration of monitoring'</a>.)</p><p></p><p class="headingAnchor" id="H11183979"><span class="h1">CATEGORY III PATTERN: ABNORMAL</span><span class="headingEndMark"> — </span>This pattern is considered abnormal because studies have demonstrated an increased risk for fetal hypoxic acidemia when the diagnostic criteria for a category III pattern are present [<a href="#rid17">17,18</a>]. Perinatal asphyxia has a range of outcomes, including normal, mild to severe neurological deficits, and death.(See  <a class="medical medical_review" href="/d/html/6205.html" rel="external">"Etiology and pathogenesis of neonatal encephalopathy"</a> and  <a class="medical medical_review" href="/d/html/6216.html" rel="external">"Clinical features, diagnosis, and treatment of neonatal encephalopathy"</a>.)</p><p class="headingAnchor" id="H1267966372"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>A category III pattern is defined by:</p><p class="bulletIndent1"><span class="glyph">●</span>Absent baseline FHR variability (ie, amplitude undetectable) and any of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bradycardia</p><p class="bulletIndent2"><span class="glyph">•</span>Recurrent late decelerations  (<a class="graphic graphic_waveform graphicRef67464" href="/d/graphic/67464.html" rel="external">waveform 2A</a> and <a class="graphic graphic_waveform graphicRef96432" href="/d/graphic/96432.html" rel="external">waveform 3</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Recurrent variable decelerations  (<a class="graphic graphic_waveform graphicRef86060" href="/d/graphic/86060.html" rel="external">waveform 2B</a>)</p><p></p><p class="bulletIndent1">Recurrent decelerations are defined as occurring with at least 50 percent of uterine contractions in a 20-minute window [<a href="#rid5">5,19</a>]. Lack of interobserver agreement about absent versus minimal variability (ie, amplitude 0 to 5 bpm) is a common problem in clinical practice [<a href="#rid3">3,20</a>]. For this reason, management strategies for category III patterns tend to be the same whether variability is absent or minimal [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/418.html" rel="external">"Intrapartum fetal heart rate monitoring: Overview"</a>.)</p><p></p><p class="bulletIndent3">OR</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A sinusoidal pattern  (<a class="graphic graphic_waveform graphicRef61189" href="/d/graphic/61189.html" rel="external">waveform 2C</a>)</p><p></p><p class="headingAnchor" id="H3281746942"><span class="h2">Management of nonsinusoidal category III pattern</span></p><p class="headingAnchor" id="H1459067466"><span class="h3">General approach</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perform scalp stimulation</strong> – Scalp stimulation should be attempted as it is a quick, minimally invasive, and informative maneuver to further evaluate the fetus. When scalp stimulation induces an acceleration, the probability of fetal pH &lt;7.20 is less than 10 percent versus approximately 50 percent when no acceleration occurs in this setting [<a href="#rid22">22-25</a>]. The technique and evidence of efficacy are described separately. (See  <a class="medical medical_review" href="/d/html/418.html" rel="external">"Intrapartum fetal heart rate monitoring: Overview", section on 'FHR response to stimulation'</a>.)</p><p></p><p class="bulletIndent1">Other methods of fetal evaluation are either no longer widely available (fetal scalp blood sampling) or not useful (fetal electrocardiogram or pulse oximetry). These methods are reviewed separately. (See  <a class="medical medical_review" href="/d/html/418.html" rel="external">"Intrapartum fetal heart rate monitoring: Overview", section on 'Less common ancillary tests'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prepare for operative delivery</strong> – Preparations for operative delivery should be made while initiating resuscitative measures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Begin in utero resuscitation </strong> (<a class="graphic graphic_table graphicRef57979" href="/d/graphic/57979.html" rel="external">table 3</a>) – The following resuscitative measures are aimed at improving uteroplacental perfusion and fetal oxygenation. Multiple interventions are generally applied simultaneously. Data from randomized trials on the efficacy of in utero resuscitation are not available.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reposition</strong> the patient onto their left or right side to relieve any compression of the umbilical cord or maternal great vessels, which may improve utero-placental-fetal perfusion [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent2">If lateral positioning is ineffective and the FHR tracing shows recurrent variable decelerations, a prolonged deceleration, or bradycardia, try a knee-chest or all fours position  (<a class="graphic graphic_figure graphicRef138959" href="/d/graphic/138959.html" rel="external">figure 1</a>) to relieve possible cord compression.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Administer an intravenous (IV) fluid bolus</strong> (eg, 500 to 1000 mL of <a class="drug drug_general" data-topicid="108196" href="/d/drug information/108196.html" rel="external">Lactated Ringer</a> or normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> solution). Although no randomized trials have evaluated the effect of IV fluid boluses alone on fetal heart abnormalities, an IV fluid bolus of a nonglucose containing crystalloid solution can improve uteroplacental blood flow and fetal oxygenation if the patient is hypovolemic from prolonged lack of oral or IV intake, vomiting, or sympathetic blockade, and thus may improve fetal oxygenation [<a href="#rid26">26,27</a>]. However, fluids should be administered cautiously in patients at increased risk of volume overload, such as patients with preeclampsia or heart disease and those who are receiving beta-adrenergic agonists for tocolysis.</p><p></p><p class="bulletIndent2">Glucose-free solutions should be used because acute maternal glucose infusion can cause fetal hyperglycemia, metabolic acidosis, and neonatal hypoglycemia [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Discontinue uterotonic drugs</strong> to improve utero-placental-fetal blood flow, which is reduced during contractions. Discontinuation of uterotonic drugs often provides adequate uterine relaxation to correct FHR abnormalities in patients receiving these drugs.</p><p></p><p class="bulletIndent2">Patients not receiving uterotonic drugs can be told to stop pushing temporarily or to push with every other contraction or they can be given a tocolytic.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Administer a tocolytic</strong> (eg, <a class="drug drug_general" data-topicid="9977" href="/d/drug information/9977.html" rel="external">terbutaline</a> 250 mcg subcutaneously) if the category III FHR pattern persists after discontinuation of uterotonic drugs or in the absence of their use, unless abruption is suspected. Tachysystole (defined as more than five contractions in 10 minutes, averaged over a 30-minute window [<a href="#rid16">16</a>]), prolonged contractions, or any contractile activity that exceeds the compensatory mechanism of the specific fetoplacental unit can reduce utero-placental-fetal blood flow. Uterine relaxation may improve blood flow and, in turn, fetal oxygenation. In a meta-analysis of acute tocolysis for intrapartum nonreassuring fetal status (four trials, 605 pregnancies with nonreassuring FHR tracings), compared with emergency cesarean birth, acute tocolysis improved neonatal acid-base status (reduced prevalence of base deficit &gt;12 mmol/L: odds ratio [OR] 0.61, 95% CI 0.37-0.99) and reduced neonatal intensive care unit (NICU) admission (OR 0.42, 95% CI 0.22-0.78) despite an increased time-to-delivery interval (mean difference 17.62 minutes, 95% CI 15.66-19.58) [<a href="#rid29">29</a>]. True maternal and neonatal benefits remain uncertain, given that the overall cesarean birth rate was similar for both groups and the improvement in neonatal acid-base status had a wide confidence interval approaching 1.0.</p><p></p><p class="bulletIndent2">Uterine relaxation may also be induced with one or two doses of IV <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> (50 mcg). The onset of uterine relaxation occurs within 30 seconds to two minutes and lasts only a minute or two [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Consult with the anesthesia team in patients who were recently given neuraxial drugs for labor pain</strong>. If maternal hypotension secondary to recent epidural dosing is identified, administering an alpha-adrenergic agonist (such as <a class="drug drug_general" data-topicid="9768" href="/d/drug information/9768.html" rel="external">phenylephrine</a> or <a class="drug drug_general" data-topicid="9114" href="/d/drug information/9114.html" rel="external">ephedrine</a>) and an IV fluid bolus is corrective and will improve utero-placental-fetal blood flow. These medications should be administered by someone with expertise in their dosing and side effects. Whether medication is indicated even in the absence of hypotension is an individualized decision as reduced placental perfusion from sympathetic blockade can occur without marked changes in maternal blood pressure.</p><p></p><p class="bulletIndent2">The administration of opioids intrathecally may induce a tetanic uterine contraction leading to transient fetal bradycardia [<a href="#rid31">31</a>]. As discussed above, uterine hypertonus may be reversed with one or two doses of IV <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> (50 mcg). The onset of uterine relaxation occurs within 30 seconds to two minutes and lasts only a minute or two [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/4469.html" rel="external">"Adverse effects of neuraxial analgesia and anesthesia for obstetrics", section on 'Hypotension'</a> and  <a class="medical medical_review" href="/d/html/4469.html" rel="external">"Adverse effects of neuraxial analgesia and anesthesia for obstetrics", section on 'Fetal bradycardia'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of amnioinfusion</strong> – Amnioinfusion is generally not indicated with category III patterns. If considered, it should only be used for a category III pattern with recurrent variable decelerations and delivery should be undertaken promptly if the decelerations do not rapidly diminish or resolve. (See  <a class="medical medical_review" href="/d/html/5383.html" rel="external">"Amnioinfusion"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of maternal oxygen supplementation</strong> – Maternal oxygen supplementation is appropriate when treating maternal hypoxemia. It has no role in fetal resuscitation in parturients with normal respiratory function. (See <a class="local">'Interventions of no or uncertain benefit'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assess results and act</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If fetal stimulation and/or in utero resuscitation promptly leads to resolution of the category III tracing, then continue maternal and fetal monitoring as appropriate for the FHR pattern (category I or II). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If scalp stimulation does not result in a FHR acceleration and the FHR tracing does not improve after resuscitative measures, then delivery should be expedited since a 10-minute period of a category III pattern, particularly with a large total area of deceleration, is associated with acidemia [<a href="#rid32">32</a>]. However, the time from this decision to delivery should consider the health of both mother and fetus: there may be circumstances (eg, difficult maternal airway, maternal coagulopathy, severe obesity) when safe delivery cannot be performed expeditiously.</p><p></p><p class="bulletIndent2">It is also important to consider the probable underlying cause(s) of the category III pattern, as urgent delivery is necessary in some acute settings, such as uterine rupture, visible cord prolapse, or severe abruption, but may be delayed in less urgent settings to treat maternal acute illness, such as sepsis, trauma, or diabetic ketoacidosis. Physician judgment plays an important role in assessing the probable cause of the category III pattern, choosing the appropriate interventions for the specific patient setting, assessing the response to those interventions, and timing of cesarean or assisted vaginal birth if the category III pattern persists.</p><p></p><p class="headingAnchor" id="H3188931625"><span class="h3">Interventions of no or uncertain benefit</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supplemental oxygen for nonhypoxemic parturients </strong>– In a nonhypoxemic mother, the underlying causes of fetal hypoxemia need to be addressed (eg, maternal hypotension or hypovolemia, cord compression, tachysystole, abruption) because maternal oxygen administration will not correct fetal acidemia [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1">In a 2021 meta-analysis of 16 randomized trials comparing oxygen supplementation versus room air for intrauterine resuscitation (n = 1078 oxygen, n = 974 room air), oxygen supplementation resulted in no clinically relevant improvement in umbilical artery (UA) pH or other neonatal outcomes (eg, Apgar scores, neonatal intensive care unit [NICU] admissions) [<a href="#rid34">34</a>]. The trials included patients with singleton, nonanomalous pregnancies in labor or patients undergoing scheduled cesarean birth.</p><p></p><p class="bulletIndent1">When stratified for the presence or absence of labor, oxygen administration in patients undergoing scheduled cesarean increased UA partial pressure of oxygen (PaO<sub>2</sub>; weighted mean difference [WMD] 2.12 mmHg, 95% CI 0.09-4.15 mmHg) and reduced the incidence of UA pH less than 7.2 (relative risk [RR] 0.63, 95% CI 0.43-0.90); these changes were not noted among those in labor (PaO<sub>2</sub>: WMD 3.60 mmHg, 95% CI -0.30 to 7.49 mmHg; UA pH &lt;7.2, RR 1.34, 95% CI 0.58-3.11). A limitation of the analysis was that it did not specifically assess use of oxygen for management of abnormal FHR tracings. If maternal hyperoxemia is achieved, a therapeutic effect on recurrent late decelerations due to impaired placenta-to-fetus oxygen delivery is plausible; however, data from underpowered randomized trials have not shown a statistically significant improvement [<a href="#rid35">35</a>].</p><p></p><p class="headingAnchor" id="H1318767372"><span class="h2">Management of sinusoidal category III pattern</span><span class="headingEndMark"> — </span>True sinusoidal FHR patterns are exceedingly rare and thus intervention has not been studied systematically.</p><p class="bulletIndent1"><span class="glyph">●</span>The pattern has been associated with severe fetal anemia, some opioids (eg, <a class="drug drug_general" data-topicid="9608" href="/d/drug information/9608.html" rel="external">meperidine</a>, alphaprodine [Nisentil], <a class="drug drug_general" data-topicid="9179" href="/d/drug information/9179.html" rel="external">butorphanol</a>, <a class="drug drug_general" data-topicid="9676" href="/d/drug information/9676.html" rel="external">nalbuphine</a> hydrochloride), and hypoxia with acidosis [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/d/html/6806.html" rel="external">"Spontaneous massive fetomaternal hemorrhage", section on 'Clinical presentation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Delivery is generally indicated if resuscitative measures do not improve the pattern. However, if the pregnancy (including the intrapartum course) was uncomplicated, the sinusoidal appears to be related to recent administration of an opioid, and the FHR pattern was normal until administration, then the pattern may be transient and unrelated to fetal hypoxia/acidosis. Sinusoidal pattern has observed 19 minutes after alphaprodine administration and lasting 60 minutes [<a href="#rid37">37</a>].</p><p></p><p class="headingAnchor" id="H11183986"><span class="h1">CATEGORY II PATTERN (INDETERMINATE)</span><span class="headingEndMark"> — </span>This pattern is of uncertain clinical significance because they are not predictive of current abnormal fetal acid-base status and the potential for future development of fetal acidosis varies widely across the different types of category II patterns. The American College of Obstetricians and Gynecologists (ACOG) considers category II tracings as indeterminate as they comprise a diverse spectrum of FHR patterns that require evaluation, ongoing surveillance, initiation of appropriate corrective measures, and reevaluation [<a href="#rid16">16</a>]. The Society of Obstetricians and Gynaecologists of Canada classifies these tracings as "atypical" [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H4204498425"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>Category II FHR patterns include all FHR patterns that are not classified as category I (normal) or category III (abnormal)  (<a class="graphic graphic_table graphicRef57583" href="/d/graphic/57583.html" rel="external">table 1B</a>). (See <a class="local">'Category I pattern: Normal'</a> above and <a class="local">'Category III pattern: Abnormal'</a> above.). </p><p class="headingAnchor" id="H575562757"><span class="h2">Management</span></p><p class="headingAnchor" id="H1053563"><span class="h3">General approach</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perform scalp stimulation</strong> – As discussed above, scalp stimulation should be attempted as it is a quick, minimally invasive, and informative maneuver to further evaluate the fetus. When scalp stimulation induces an acceleration, the probability of fetal pH &lt;7.20 is less than 10 percent versus approximately 50 percent when no acceleration occurs in this setting [<a href="#rid22">22-25,39-41</a>]. (See  <a class="medical medical_review" href="/d/html/418.html" rel="external">"Intrapartum fetal heart rate monitoring: Overview", section on 'FHR response to stimulation'</a>.)</p><p></p><p class="bulletIndent1">Other methods of fetal evaluation are either no longer widely available (fetal scalp blood sampling) or not useful (fetal electrocardiogram or pulse oximetry). These methods are reviewed separately. (See  <a class="medical medical_review" href="/d/html/418.html" rel="external">"Intrapartum fetal heart rate monitoring: Overview", section on 'Less common ancillary tests'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assess variability</strong> – Moderate variability (ie, amplitude 6 to 25 bpm) is strongly associated (98 percent) with absence of fetal acidosis [<a href="#rid39">39,42-44</a>]. (See  <a class="medical medical_review" href="/d/html/418.html" rel="external">"Intrapartum fetal heart rate monitoring: Overview", section on 'Fetal scalp blood sampling'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluate for factors that may reduce fetal oxygenation</strong> – Clinical scenarios associated with intrapartum fetal compromise include abruption, uterine rupture from a trial of labor after a previous cesarean birth, fetal growth restriction, preeclampsia with severe features, and severe fetal anemia. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initiate one or more of resuscitative measures, </strong>as described above. (See <a class="local">'General approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Frequently reassess</strong>, taking into account the stage and progress of labor, to determine whether to perform an operative intervention and the urgency of the intervention. Continued surveillance and frequent reassessment are indicated until the pattern resolves to category I or progresses to category III, which develops when fetal compensatory mechanisms fail to maintain adequate cerebral and tissue oxygenation, leading to fetal acidosis. Expeditious delivery of these fetuses is indicated. Timely and effective intervention before acidemia becomes severe may prevent perinatal morbidity or mortality [<a href="#rid45">45</a>]. (See <a class="local">'Category III pattern: Abnormal'</a> above.)</p><p></p><p class="bulletIndent1">However, there are virtually no data to inform decision-making as to how long to monitor a fetus with a persistent category II tracing despite use of standard resuscitative measures.</p><p></p><p>Because of the wide spectrum and significance of category II patterns, various decision aids have been created to help with their identification, interpretation, and management, but these systems have not been well-validated. (See  <a class="medical medical_review" href="/d/html/418.html" rel="external">"Intrapartum fetal heart rate monitoring: Overview", section on 'Use of decision/interpretation aids and algorithms'</a>.)</p><p class="headingAnchor" id="H4241721886"><span class="h3">Approach to selected category II patterns</span></p><p class="headingAnchor" id="H11183993"><span class="h4">Late decelerations without loss of variability</span><span class="headingEndMark"> — </span>Recurrent late decelerations are a reflex central nervous system (CNS) response to fetal hypoxia and acidemia, as well as direct myocardial depression and humoral factors [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/d/html/418.html" rel="external">"Intrapartum fetal heart rate monitoring: Overview", section on 'Late deceleration'</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identify the potential source</strong> – Recurrent late decelerations may occur in the following settings:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Uterine tachysystole</p><p class="bulletIndent2"><span class="glyph">•</span>Maternal hypotension</p><p class="bulletIndent2"><span class="glyph">•</span>Maternal hypoxia</p><p class="bulletIndent2"><span class="glyph">•</span>Maternal acidemia</p><p class="bulletIndent2"><span class="glyph">•</span>Maternal vasculopathy</p><p class="bulletIndent2"><span class="glyph">•</span>Placental disorders associated with placental insufficiency</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The general approach is described above (see <a class="local">'General approach'</a> above). Assessment of FHR variability and accelerations is important, given the low predictive value of late decelerations alone for fetal acidosis and poor neonatal outcome [<a href="#rid47">47-49</a>]. Moderate variability is strongly associated (98 percent) with an umbilical pH &gt;7.15 [<a href="#rid39">39</a>] and spontaneous or elicited FHR accelerations are strongly associated with pH &gt;7.2 [<a href="#rid22">22-25</a>]. (See  <a class="medical medical_review" href="/d/html/418.html" rel="external">"Intrapartum fetal heart rate monitoring: Overview", section on 'FHR response to stimulation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The duration of time for which it is safe to closely monitor a category II tracing with late decelerations associated with moderate variability and/or accelerations depends on the specific clinical scenario, particularly whether the potential source is reversible or can be ameliorated with resuscitative maneuvers.</p><p></p><p class="headingAnchor" id="H11184000"><span class="h4">Fetal tachycardia</span><span class="headingEndMark"> — </span>Fetal tachycardia is defined as a baseline FHR greater than 160 bpm for at least 10 minutes. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identify the potential source</strong> – Causes of fetal tachycardia include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Maternal-fetal infection </p><p class="bulletIndent2"><span class="glyph">•</span>Medications (eg, beta-agonists, <a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">atropine</a>, cocaine)</p><p class="bulletIndent2"><span class="glyph">•</span>Maternal hyperthyroidism</p><p class="bulletIndent2"><span class="glyph">•</span>Placental abruption</p><p class="bulletIndent2"><span class="glyph">•</span>Fetal hypoxia</p><p class="bulletIndent2"><span class="glyph">•</span>Elevated maternal catecholamine levels</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The general approach is described above. (See <a class="local">'General approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The evaluation of fetal tachycardia should include assessment for maternal infection or abruption and a review of maternal medications. Appropriate treatment should be initiated if the underlying cause can be identified and treated (eg, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> for reduction of fever and antibiotics for treatment of intraamniotic infection). Delivery is indicated if acidemia or placental abruption is suspected. Tachycardia due to chorioamnionitis is generally not an indication for delivery unless decelerations or category III pattern is present, or if the patient is remote from delivery and the tachycardia does not resolve with maternal hydration and antipyretic therapy. (See  <a class="medical medical_review" href="/d/html/6803.html" rel="external">"Acute placental abruption: Management and long-term prognosis"</a> and  <a class="medical medical_review" href="/d/html/6762.html" rel="external">"Clinical chorioamnionitis", section on 'Initiate delivery'</a>.)</p><p></p><p class="bulletIndent2">Isolated fetal tachycardia less than 200 bpm has not been strongly associated with fetal acidemia [<a href="#rid50">50-53</a>]. Rarely, fetal tachycardia can be due to a fetal tachyarrhythmia, such as atrial flutter or supraventricular tachycardia. These tachyarrhythmias are characterized by a very high FHR, often in excess of 200 bpm, and may lead to hydrops fetalis. (See  <a class="medical medical_review" href="/d/html/6765.html" rel="external">"Fetal arrhythmias", section on 'Tachyarrhythmias'</a>.)</p><p></p><p class="headingAnchor" id="H11184007"><span class="h4">Variable decelerations without loss of variability or accelerations</span><span class="headingEndMark"> — </span>Variable decelerations occur when the umbilical cord is compressed. (See  <a class="medical medical_review" href="/d/html/418.html" rel="external">"Intrapartum fetal heart rate monitoring: Overview", section on 'Variable deceleration'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identify the potential source</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oligohydramnios</p><p class="bulletIndent2"><span class="glyph">•</span>Umbilical cord prolapse</p><p class="bulletIndent2"><span class="glyph">•</span>Nuchal cord, knot in cord </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intermittent variable decelerations (associated with &lt;50 percent of contractions) are frequently observed intrapartum and usually associated with moderate variability and/or accelerations. They do not typically result in adverse consequences, presumably because transient cord compression is well tolerated by the fetus [<a href="#rid54">54</a>]. Thus, they do not require intervention. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Metabolic acidosis or mixed metabolic and respiratory acidosis can develop with increasing duration, depth, and frequency of variable decelerations [<a href="#rid55">55</a>]. Therefore, recurrent variable decelerations (&gt;50 percent of contractions) require close surveillance for loss of variability and accelerations, which signify a category III pattern. (See <a class="local">'Category III pattern: Abnormal'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A vaginal examination is performed to assess for cord prolapse.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>One or more in utero resuscitation measures are initiated, with the major focus to resolve cord compression. Change of maternal position is a reasonable first treatment option [<a href="#rid56">56</a>]. (See <a class="local">'General approach'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Amnioinfusion is a reasonable second-line option. In a meta-analysis of randomized trials comparing amnioinfusion with no amnioinfusion in patients with potential cord compression because of oligohydramnios or suspected cord compression because of variable FHR decelerations, amnioinfusion resulted in a 50 to 60 percent reduction in FHR abnormalities compared with controls [<a href="#rid57">57</a>]. There was a reduction in the number of cesarean births performed because of FHR abnormalities (risk ratio [RR] 0.46, 95% CI 0.31-0.68) and improvement in several neonatal outcomes, including a trend toward fewer neonates with umbilical artery (UA) pH &lt;7.2 (RR 0.58, 95% CI 0.29-1.14). However, more research is needed to confirm the findings since longer-term measures of fetal/neonatal outcome were not assessed, the diagnosis of fetal distress in the trials was not stringent, and the value in specific clinical situations, such as FHR decelerations, oligohydramnios, or prelabor rupture of membranes was not evaluated. Patients with low preamnioinfusion amniotic fluid volume are most likely to experience resolution of variable decelerations with amnioinfusion. In patients with a high amniotic fluid volume (amniotic fluid index &gt;12 cm) and variable decelerations, a nuchal cord or umbilical cord knot is a more likely cause of the variable pattern than reduced amniotic fluid, so amnioinfusion is less likely to be beneficial [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/d/html/5383.html" rel="external">"Amnioinfusion"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Delivery is indicated if a category III pattern develops. (See <a class="local">'Category III pattern: Abnormal'</a> above.)</p><p></p><p class="headingAnchor" id="H11184014"><span class="h4">Loss of variability without decelerations</span><span class="headingEndMark"> — </span>FHR variability results from oscillatory input by the parasympathetic nervous system. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identify the potential source</strong> – The new onset of minimal variability (amplitude 0 to 5 bpm) may occur for several reasons, including [<a href="#rid59">59-61</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fetal sleep cycle – These cycles generally last approximately 20 minutes, but may persist for as long as one hour. When the fetal sleep cycles are over, moderate variability should return.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CNS depressants – The most common medications that decrease variability are opioids and <a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">magnesium sulfate</a>. The effect of maternal opioids on FHR variability generally lasts no more than two hours.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fetal hypoxemia</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antenatal corticosteroids</p><p></p><p class="bulletIndent1">Long-standing loss of variability can be related to congenital or acquired anomalies of the CNS or heart, or to very preterm gestation [<a href="#rid62">62-64</a>]. Antenatal corticosteroid administration has been associated with a decrease in variability on days 2 and 3 after administration [<a href="#rid65">65-69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the FHR pattern had been normal and there are no decelerations, a reasonable approach to the assessment and management of new-onset minimal fetal variability is to make a presumptive diagnosis of a fetal sleep cycle or the effect of recently administered maternal medications and continue routine intrapartum care. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>It is also prudent to attempt to induce accelerations with scalp stimulation, as the presence of accelerations is strong evidence of the absence of fetal acidemia at that time [<a href="#rid23">23</a>]. Clinicians should have a plan for cases in which no acceleration occurs after scalp stimulation. In general, if the tracing does not improve, delivery is indicated. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A maternal fluid bolus and repositioning are appropriate adjunctive measures  (<a class="graphic graphic_table graphicRef57979" href="/d/graphic/57979.html" rel="external">table 3</a>), especially in settings in which a benign etiology is less certain, such as coexistent pregnancy complications associated with uteroplacental insufficiency. (See <a class="local">'General approach'</a> above.)</p><p></p><p class="headingAnchor" id="H11184021"><span class="h4">Fetal bradycardia/prolonged deceleration without loss of variability</span><span class="headingEndMark"> — </span>Fetal bradycardia (below 110 bpm) and a prolonged deceleration  (<a class="graphic graphic_table graphicRef65859" href="/d/graphic/65859.html" rel="external">table 1A</a>) are approached similarly, since the distinction between these two entities is based primarily on the number of minutes of the decrease in FHR. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identify the potential cause</strong> – The causes of prolonged deceleration or fetal bradycardia include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rapid fetal descent</p><p class="bulletIndent2"><span class="glyph">•</span>Cord prolapse/sustained cord compression</p><p class="bulletIndent2"><span class="glyph">•</span>Placental abruption</p><p class="bulletIndent2"><span class="glyph">•</span>Maternal hypotension</p><p class="bulletIndent2"><span class="glyph">•</span>Uterine rupture</p><p class="bulletIndent2"><span class="glyph">•</span>Tachysystole</p><p class="bulletIndent2"><span class="glyph">•</span>Acute fetal hemorrhage</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment of fetal bradycardia or prolonged deceleration is aimed at the cause, which may be reversible or irreversible. Evaluation should include assessment of maternal blood pressure and contraction frequency and strength, and physical examination for evidence of rapid fetal descent, cord prolapse, abruption, or uterine rupture. (See  <a class="medical medical_review" href="/d/html/4461.html" rel="external">"Umbilical cord prolapse"</a> and  <a class="medical medical_review" href="/d/html/14210.html" rel="external">"Uterine rupture: Unscarred uterus"</a> and  <a class="medical medical_review" href="/d/html/6826.html" rel="external">"Acute placental abruption: Pathophysiology, clinical features, diagnosis, and consequences"</a> and  <a class="medical medical_review" href="/d/html/87237.html" rel="external">"Uterine rupture: After previous cesarean birth"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Delivery is indicated if resuscitative measures to correct the underlying cause are not possible or fail to resolve the bradycardia. In one study of 5388 term, singleton pregnancies at full dilation with a nonanomalous fetus in cephalic presentation, a terminal deceleration occurred in 951 (17.7 percent) and 12 (1.3 percent) had umbilical cord gas arterial pH &lt;7.10 [<a href="#rid70">70</a>]. Of the 31 who had terminal bradycardia (FHR &lt;110 bpm for ≥10 minutes before delivery), four had an umbilical cord gas arterial pH ≤7.10. Although infants with terminal bradycardia were at increased risk of acidemia, the positive predictive value was only 12.9 percent. The authors also noted a positive association between increasing duration of a terminal deceleration beyond two minutes and decreasing pH (pH decreased by 0.042 for every additional two minutes after the first two minutes).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Delivery is also indicated for development of a category III tracing.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the FHR returns to a normal baseline rate and variability and accelerations are present, fetal acidemia is unlikely.</p><p></p><p class="headingAnchor" id="H193118964"><span class="h1">PREVALENCE OF CATEGORY I, II, AND III PATTERNS DURING LABOR</span><span class="headingEndMark"> — </span>Most parturients have a category I pattern for most of the intrapartum period, although the prevalence of category I patterns decreases and the prevalence of both category II and III patterns increases near delivery. For example, in a study of the intrapartum FHR characteristics of over 48,000 patients in labor with a singleton, nonanomalous fetus at term in 10 hospitals [<a href="#rid71">71</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>At some point during labor:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Category I patterns were present in over 99 percent of tracings </p><p class="bulletIndent2"><span class="glyph">•</span>Category II patterns were present in 84 percent of tracings</p><p class="bulletIndent2"><span class="glyph">•</span>Category III patterns were present in 0.1 percent of tracings</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Over the course of labor:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Category I patterns were present 78 percent of the time</p><p class="bulletIndent2"><span class="glyph">•</span>Category II patterns were present 22 percent of the time</p><p class="bulletIndent2"><span class="glyph">•</span>Category III patterns were present 0.004 percent of the time</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the two hours before delivery:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Category I were present in 61 percent of tracings</p><p class="bulletIndent2"><span class="glyph">•</span>Category II tracings were present in 39 percent of tracings</p><p class="bulletIndent2"><span class="glyph">•</span>Category III tracings were present in 0.006 percent</p><p></p><p class="headingAnchor" id="H4282585971"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113525.html" rel="external">"Society guideline links: Labor"</a>.)</p><p class="headingAnchor" id="H11184028"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Three-tier system of classification</strong> – The three-tier system for the categorization of intrapartum fetal heart rate (FHR) tracings  (<a class="graphic graphic_table graphicRef65859 graphicRef57583" href="/d/graphic/65859.html" rel="external">table 1A-B</a>) is a useful means of approaching management  (<a class="graphic graphic_table graphicRef71679" href="/d/graphic/71679.html" rel="external">table 4</a>). The risk of adverse neonatal outcomes increases with increasing tier, but the majority of newborns even with category III tracings do not have adverse outcomes. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Category I tracings</strong> – Category I tracings  (<a class="graphic graphic_waveform graphicRef86064" href="/d/graphic/86064.html" rel="external">waveform 1</a>) are normal and not associated with fetal metabolic acidemia at the time of observation. Low-risk patients with category I tracings may be followed intermittently, with reapplication of the monitor and reassessment of the tracing at least every 30 minutes in the first stage of labor and every 15 minutes in the second stage. High-risk patients (ie, those with risk factors that increase the risk for a complicated birth) are typically monitored continuously because of a greater potential for change to a category II or III pattern and practicality. (See <a class="local">'Category I pattern: Normal'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Category III tracings</strong> – Category III tracings  (<a class="graphic graphic_waveform graphicRef67464 graphicRef86060 graphicRef61189" href="/d/graphic/67464.html" rel="external">waveform 2A-C</a>) are abnormal and associated with an increased risk of fetal hypoxic acidemia. Patients with category III tracings should be prepared for delivery while initiating resuscitative measures  (<a class="graphic graphic_table graphicRef57979" href="/d/graphic/57979.html" rel="external">table 3</a>). If there is no improvement in the tracing after resuscitative measures and scalp stimulation does not result in FHR acceleration, delivery should be accomplished expeditiously, but ensuring maternal safety. (See <a class="local">'Category III pattern: Abnormal'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Category II tracings </strong>– The potential for development of fetal acidosis varies widely across the different types of category II tracings. Patients with these tracings should be evaluated for factors that may reduce fetal oxygenation, taking into account associated clinical circumstances (eg, abruption, fetal growth restriction, trial of labor after cesarean, stage of labor, decelerations/bradycardia). An attempt at in utero resuscitation rather than operative delivery is usually appropriate  (<a class="graphic graphic_table graphicRef57979" href="/d/graphic/57979.html" rel="external">table 3</a>), with frequent reassessment to determine whether operative delivery should be performed. Moderate variability or FHR accelerations generally excludes hypoxic injury at that time and warrants continued surveillance, as long as labor progress is normal and no condition associated with rapid fetal compromise (eg, abruption, uterine rupture) is present. (See <a class="local">'Category II pattern (Indeterminate)'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Nielsen PV, Stigsby B, Nickelsen C, Nim J. Intra- and inter-observer variability in the assessment of intrapartum cardiotocograms. Acta Obstet Gynecol Scand 1987; 66:421.</a></li><li><a class="nounderline abstract_t">Beaulieu MD, Fabia J, Leduc B, et al. The reproducibility of intrapartum cardiotocogram assessments. Can Med Assoc J 1982; 127:214.</a></li><li><a class="nounderline abstract_t">Chauhan SP, Klauser CK, Woodring TC, et al. Intrapartum nonreassuring fetal heart rate tracing and prediction of adverse outcomes: interobserver variability. Am J Obstet Gynecol 2008; 199:623.e1.</a></li><li><a class="nounderline abstract_t">Macones GA, Hankins GD, Spong CY, et al. The 2008 National Institute of Child Health and Human Development workshop report on electronic fetal monitoring: update on definitions, interpretation, and research guidelines. Obstet Gynecol 2008; 112:661.</a></li><li><a class="nounderline abstract_t">Electronic fetal heart rate monitoring: research guidelines for interpretation. National Institute of Child Health and Human Development Research Planning Workshop. Am J Obstet Gynecol 1997; 177:1385.</a></li><li><a class="nounderline abstract_t">Ayres-de-Campos D, Spong CY, Chandraharan E, FIGO Intrapartum Fetal Monitoring Expert Consensus Panel. FIGO consensus guidelines on intrapartum fetal monitoring: Cardiotocography. Int J Gynaecol Obstet 2015; 131:13.</a></li><li class="breakAll">Intrapartum care: NICE guideline CG190. Interpretation of cardiograph traces. (February 2017) https://www.nice.org.uk/guidance/cg190/resources/interpretation-of-cardiotocograph-traces-pdf-248732173 (Accessed on June 17, 2022).</li><li class="breakAll">Cardiotocograph (CTG) Interpretation and Response. The Women's Royal Hospital, Victoria, Australia. Available at: https://thewomens.r.worldssl.net/images/uploads/downloadable-records/clinical-guidelines/ctg-interpretation-and-response_280720.pdf (Accessed on June 17, 2022).</li><li><a class="nounderline abstract_t">Okai T, Ikeda T, Kawarabayashi T, et al. Intrapartum management guidelines based on fetal heart rate pattern classification. J Obstet Gynaecol Res 2010; 36:925.</a></li><li><a class="nounderline abstract_t">Dore S, Ehman W. No. 396-Fetal Health Surveillance: Intrapartum Consensus Guideline. J Obstet Gynaecol Can 2020; 42:316.</a></li><li><a class="nounderline abstract_t">Zullo F, Di Mascio D, Raghuraman N, et al. Three-tiered fetal heart rate interpretation system and adverse neonatal and maternal outcomes: a systematic review and meta-analysis. Am J Obstet Gynecol 2023; 229:377.</a></li><li><a class="nounderline abstract_t">Berkus MD, Langer O, Samueloff A, et al. Electronic fetal monitoring: what's reassuring? Acta Obstet Gynecol Scand 1999; 78:15.</a></li><li><a class="nounderline abstract_t">Krebs HB, Petres RE, Dunn LJ, Smith PJ. Intrapartum fetal heart rate monitoring. VI. Prognostic significance of accelerations. Am J Obstet Gynecol 1982; 142:297.</a></li><li><a class="nounderline abstract_t">Tejani N, Mann LI, Bhakthavathsalan A, Weiss RR. Correlation of fetal heart rate-uterine contraction patterns with fetal scalp blood pH. Obstet Gynecol 1975; 46:392.</a></li><li><a class="nounderline abstract_t">Dellinger EH, Boehm FH, Crane MM. Electronic fetal heart rate monitoring: early neonatal outcomes associated with normal rate, fetal stress, and fetal distress. Am J Obstet Gynecol 2000; 182:214.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 106: Intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles. Obstet Gynecol 2009; 114:192. Reaffirmed 2021.</a></li><li class="breakAll">American Academy of Pediatrics, American College of Obstetricians and Gynecologists. Neonatal encephalopathy and cerebral palsy: defining the pathogenesis and pathophysiology. Elk Grove Village (IL): AAP; ACOG, Washington, DC 2003.</li><li><a class="nounderline abstract_t">Frey HA, Liu X, Lynch CD, et al. An evaluation of fetal heart rate characteristics associated with neonatal encephalopathy: a case-control study. BJOG 2018; 125:1480.</a></li><li><a class="nounderline abstract_t">Macones GA, Hankins GD, Spong CY, et al. The 2008 National Institute of Child Health and Human Development workshop report on electronic fetal monitoring: update on definitions, interpretation, and research guidelines. Obstet Gynecol 2008; 112:661.</a></li><li><a class="nounderline abstract_t">Blackwell SC, Grobman WA, Antoniewicz L, et al. Interobserver and intraobserver reliability of the NICHD 3-Tier Fetal Heart Rate Interpretation System. Am J Obstet Gynecol 2011; 205:378.e1.</a></li><li><a class="nounderline abstract_t">Clark SL, Nageotte MP, Garite TJ, et al. Intrapartum management of category II fetal heart rate tracings: towards standardization of care. Am J Obstet Gynecol 2013; 209:89.</a></li><li><a class="nounderline abstract_t">Clark SL, Gimovsky ML, Miller FC. The scalp stimulation test: a clinical alternative to fetal scalp blood sampling. Am J Obstet Gynecol 1984; 148:274.</a></li><li><a class="nounderline abstract_t">Skupski DW, Rosenberg CR, Eglinton GS. Intrapartum fetal stimulation tests: a meta-analysis. Obstet Gynecol 2002; 99:129.</a></li><li><a class="nounderline abstract_t">Edersheim TG, Hutson JM, Druzin ML, Kogut EA. Fetal heart rate response to vibratory acoustic stimulation predicts fetal pH in labor. Am J Obstet Gynecol 1987; 157:1557.</a></li><li><a class="nounderline abstract_t">Smith CV, Nguyen HN, Phelan JP, Paul RH. Intrapartum assessment of fetal well-being: a comparison of fetal acoustic stimulation with acid-base determinations. Am J Obstet Gynecol 1986; 155:726.</a></li><li><a class="nounderline abstract_t">Simpson KR, James DC. Efficacy of intrauterine resuscitation techniques in improving fetal oxygen status during labor. Obstet Gynecol 2005; 105:1362.</a></li><li><a class="nounderline abstract_t">Simpson KR. Intrauterine resuscitation during labor. MCN Am J Matern Child Nurs 2005; 30:344.</a></li><li><a class="nounderline abstract_t">Pressman EK, Blakemore KJ. A prospective randomized trial of two solutions for intrapartum amnioinfusion: effects on fetal electrolytes, osmolality, and acid-base status. Am J Obstet Gynecol 1996; 175:945.</a></li><li><a class="nounderline abstract_t">Xodo S, de Heus R, Berghella V, Londero AP. Acute tocolysis for intrapartum nonreassuring fetal status: how often does it prevent cesarean delivery? A systematic review and meta-analysis of randomized controlled trials. Am J Obstet Gynecol MFM 2022; 4:100639.</a></li><li><a class="nounderline abstract_t">Mercier FJ, Dounas M, Bouaziz H, et al. Intravenous nitroglycerin to relieve intrapartum fetal distress related to uterine hyperactivity: a prospective observational study. Anesth Analg 1997; 84:1117.</a></li><li><a class="nounderline abstract_t">Clarke VT, Smiley RM, Finster M. Uterine hyperactivity after intrathecal injection of fentanyl for analgesia during labor: a cause of fetal bradycardia? Anesthesiology 1994; 81:1083.</a></li><li><a class="nounderline abstract_t">Cahill AG, Tuuli MG, Stout MJ, et al. A prospective cohort study of fetal heart rate monitoring: deceleration area is predictive of fetal acidemia. Am J Obstet Gynecol 2018; 218:523.e1.</a></li><li><a class="nounderline abstract_t">Hamel MS, Anderson BL, Rouse DJ. Oxygen for intrauterine resuscitation: of unproved benefit and potentially harmful. Am J Obstet Gynecol 2014; 211:124.</a></li><li><a class="nounderline abstract_t">Raghuraman N, Temming LA, Doering MM, et al. Maternal Oxygen Supplementation Compared With Room Air for Intrauterine Resuscitation: A Systematic Review and Meta-analysis. JAMA Pediatr 2021; 175:368.</a></li><li><a class="nounderline abstract_t">Raghuraman N, López JD, Carter EB, et al. The effect of intrapartum oxygen supplementation on category II fetal monitoring. Am J Obstet Gynecol 2020; 223:905.e1.</a></li><li><a class="nounderline abstract_t">Modanlou HD, Murata Y. Sinusoidal heart rate pattern: Reappraisal of its definition and clinical significance. J Obstet Gynaecol Res 2004; 30:169.</a></li><li><a class="nounderline abstract_t">Gray JH, Cudmore DW, Luther ER, et al. Sinusoidal fetal heart rate pattern associated with alphaprodine administration. Obstet Gynecol 1978; 52:678.</a></li><li><a class="nounderline abstract_t">Liston R, Sawchuck D, Young D. No. 197b-Fetal Health Surveillance: Intrapartum Consensus Guideline. J Obstet Gynaecol Can 2018; 40:e298.</a></li><li><a class="nounderline abstract_t">Parer JT, King T, Flanders S, et al. Fetal acidemia and electronic fetal heart rate patterns: is there evidence of an association? J Matern Fetal Neonatal Med 2006; 19:289.</a></li><li><a class="nounderline abstract_t">Lin CC, Vassallo B, Mittendorf R. Is intrapartum vibroacoustic stimulation an effective predictor of fetal acidosis? J Perinat Med 2001; 29:506.</a></li><li><a class="nounderline abstract_t">Clark SL, Gimovsky ML, Miller FC. Fetal heart rate response to scalp blood sampling. Am J Obstet Gynecol 1982; 144:706.</a></li><li><a class="nounderline abstract_t">Williams KP, Galerneau F. Intrapartum fetal heart rate patterns in the prediction of neonatal acidemia. Am J Obstet Gynecol 2003; 188:820.</a></li><li><a class="nounderline abstract_t">Low JA, Victory R, Derrick EJ. Predictive value of electronic fetal monitoring for intrapartum fetal asphyxia with metabolic acidosis. Obstet Gynecol 1999; 93:285.</a></li><li><a class="nounderline abstract_t">Cahill AG, Roehl KA, Odibo AO, Macones GA. Association and prediction of neonatal acidemia. Am J Obstet Gynecol 2012; 207:206.e1.</a></li><li><a class="nounderline abstract_t">Winkler CL, Hauth JC, Tucker JM, et al. Neonatal complications at term as related to the degree of umbilical artery acidemia. Am J Obstet Gynecol 1991; 164:637.</a></li><li><a class="nounderline abstract_t">Westgate JA, Wibbens B, Bennet L, et al. The intrapartum deceleration in center stage: a physiologic approach to the interpretation of fetal heart rate changes in labor. Am J Obstet Gynecol 2007; 197:236.e1.</a></li><li><a class="nounderline abstract_t">Nelson KB, Dambrosia JM, Ting TY, Grether JK. Uncertain value of electronic fetal monitoring in predicting cerebral palsy. N Engl J Med 1996; 334:613.</a></li><li><a class="nounderline abstract_t">Larma JD, Silva AM, Holcroft CJ, et al. Intrapartum electronic fetal heart rate monitoring and the identification of metabolic acidosis and hypoxic-ischemic encephalopathy. Am J Obstet Gynecol 2007; 197:301.e1.</a></li><li><a class="nounderline abstract_t">Paul RH, Suidan AK, Yeh S, et al. Clinical fetal monitoring. VII. The evaluation and significance of intrapartum baseline FHR variability. Am J Obstet Gynecol 1975; 123:206.</a></li><li><a class="nounderline abstract_t">Honjo S, Yamaguchi M. Umbilical artery blood acid-base analysis and fetal heart rate baseline in the second stage of labor. J Obstet Gynaecol Res 2001; 27:249.</a></li><li><a class="nounderline abstract_t">Strachan BK, Sahota DS, van Wijngaarden WJ, et al. Computerised analysis of the fetal heart rate and relation to acidaemia at delivery. BJOG 2001; 108:848.</a></li><li><a class="nounderline abstract_t">Gilstrap LC 3rd, Hauth JC, Hankins GD, Beck AW. Second-stage fetal heart rate abnormalities and type of neonatal acidemia. Obstet Gynecol 1987; 70:191.</a></li><li><a class="nounderline abstract_t">Krebs HB, Petres RE, Dunn LJ. Intrapartum fetal heart rate monitoring. V. Fetal heart rate patterns in the second stage of labor. Am J Obstet Gynecol 1981; 140:435.</a></li><li><a class="nounderline abstract_t">Garite TJ, Dildy GA, McNamara H, et al. A multicenter controlled trial of fetal pulse oximetry in the intrapartum management of nonreassuring fetal heart rate patterns. Am J Obstet Gynecol 2000; 183:1049.</a></li><li><a class="nounderline abstract_t">Frasch MG, Mansano RZ, McPhaul L, et al. Measures of acidosis with repetitive umbilical cord occlusions leading to fetal asphyxia in the near-term ovine fetus. Am J Obstet Gynecol 2009; 200:200.e1.</a></li><li><a class="nounderline abstract_t">Simpson KR. Intrauterine resuscitation during labor: review of current methods and supportive evidence. J Midwifery Womens Health 2007; 52:229.</a></li><li><a class="nounderline abstract_t">Hofmeyr GJ, Lawrie TA. Amnioinfusion for potential or suspected umbilical cord compression in labour. Cochrane Database Syst Rev 2012; 1:CD000013.</a></li><li><a class="nounderline abstract_t">Spong CY, McKindsey F, Ross MG. Amniotic fluid index predicts the relief of variable decelerations after amnioinfusion bolus. Am J Obstet Gynecol 1996; 175:1066.</a></li><li><a class="nounderline abstract_t">Giannina G, Guzman ER, Lai YL, et al. Comparison of the effects of meperidine and nalbuphine on intrapartum fetal heart rate tracings. Obstet Gynecol 1995; 86:441.</a></li><li><a class="nounderline abstract_t">Kopecky EA, Ryan ML, Barrett JF, et al. Fetal response to maternally administered morphine. Am J Obstet Gynecol 2000; 183:424.</a></li><li><a class="nounderline abstract_t">Hallak M, Martinez-Poyer J, Kruger ML, et al. The effect of magnesium sulfate on fetal heart rate parameters: A randomized, placebo-controlled trial. Am J Obstet Gynecol 1999; 181:1122.</a></li><li><a class="nounderline abstract_t">Devoe LD. Antepartum fetal heart rate testing in preterm pregnancy. Obstet Gynecol 1982; 60:431.</a></li><li><a class="nounderline abstract_t">Assali NS, Brinkman CR 3rd, Woods JR Jr, et al. Development of neurohumoral control of fetal, neonatal, and adult cardiovascular functions. Am J Obstet Gynecol 1977; 129:748.</a></li><li><a class="nounderline abstract_t">van der Moer PE, Gerretsen G, Visser GH. Fixed fetal heart rate pattern after intrauterine accidental decerebration. Obstet Gynecol 1985; 65:125.</a></li><li><a class="nounderline abstract_t">Subtil D, Tiberghien P, Devos P, et al. Immediate and delayed effects of antenatal corticosteroids on fetal heart rate: a randomized trial that compares betamethasone acetate and phosphate, betamethasone phosphate, and dexamethasone. Am J Obstet Gynecol 2003; 188:524.</a></li><li><a class="nounderline abstract_t">Mulder EJ, Derks JB, Visser GH. Antenatal corticosteroid therapy and fetal behaviour: a randomised study of the effects of betamethasone and dexamethasone. Br J Obstet Gynaecol 1997; 104:1239.</a></li><li><a class="nounderline abstract_t">Senat MV, Minoui S, Multon O, et al. Effect of dexamethasone and betamethasone on fetal heart rate variability in preterm labour: a randomised study. Br J Obstet Gynaecol 1998; 105:749.</a></li><li><a class="nounderline abstract_t">Rotmensch S, Liberati M, Vishne TH, et al. The effect of betamethasone and dexamethasone on fetal heart rate patterns and biophysical activities. A prospective randomized trial. Acta Obstet Gynecol Scand 1999; 78:493.</a></li><li><a class="nounderline abstract_t">Rotmensch S, Lev S, Kovo M, et al. Effect of betamethasone administration on fetal heart rate tracing: a blinded longitudinal study. Fetal Diagn Ther 2005; 20:371.</a></li><li><a class="nounderline abstract_t">Cahill AG, Caughey AB, Roehl KA, et al. Terminal fetal heart decelerations and neonatal outcomes. Obstet Gynecol 2013; 122:1070.</a></li><li><a class="nounderline abstract_t">Jackson M, Holmgren CM, Esplin MS, et al. Frequency of fetal heart rate categories and short-term neonatal outcome. Obstet Gynecol 2011; 118:803.</a></li></ol></div><div id="topicVersionRevision">Topic 16663 Version 56.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3425243" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Intra- and inter-observer variability in the assessment of intrapartum cardiotocograms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7104902" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The reproducibility of intrapartum cardiotocogram assessments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18667185" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Intrapartum nonreassuring fetal heart rate tracing and prediction of adverse outcomes: interobserver variability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18757666" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The 2008 National Institute of Child Health and Human Development workshop report on electronic fetal monitoring: update on definitions, interpretation, and research guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9423739" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Electronic fetal heart rate monitoring: research guidelines for interpretation. National Institute of Child Health and Human Development Research Planning Workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26433401" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : FIGO consensus guidelines on intrapartum fetal monitoring: Cardiotocography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26433401" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : FIGO consensus guidelines on intrapartum fetal monitoring: Cardiotocography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26433401" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : FIGO consensus guidelines on intrapartum fetal monitoring: Cardiotocography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21058434" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Intrapartum management guidelines based on fetal heart rate pattern classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32178781" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : No. 396-Fetal Health Surveillance: Intrapartum Consensus Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37044237" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Three-tiered fetal heart rate interpretation system and adverse neonatal and maternal outcomes: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9926886" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Electronic fetal monitoring: what's reassuring?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7065019" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Intrapartum fetal heart rate monitoring. VI. Prognostic significance of accelerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/241036" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Correlation of fetal heart rate-uterine contraction patterns with fetal scalp blood pH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10649181" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Electronic fetal heart rate monitoring: early neonatal outcomes associated with normal rate, fetal stress, and fetal distress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19546798" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : ACOG Practice Bulletin No. 106: Intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19546798" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : ACOG Practice Bulletin No. 106: Intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29575562" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : An evaluation of fetal heart rate characteristics associated with neonatal encephalopathy: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18757666" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The 2008 National Institute of Child Health and Human Development workshop report on electronic fetal monitoring: update on definitions, interpretation, and research guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21864826" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Interobserver and intraobserver reliability of the NICHD 3-Tier Fetal Heart Rate Interpretation System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23628263" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Intrapartum management of category II fetal heart rate tracings: towards standardization of care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6695974" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The scalp stimulation test: a clinical alternative to fetal scalp blood sampling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11777523" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Intrapartum fetal stimulation tests: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3425661" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Fetal heart rate response to vibratory acoustic stimulation predicts fetal pH in labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3766625" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Intrapartum assessment of fetal well-being: a comparison of fetal acoustic stimulation with acid-base determinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15932830" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy of intrauterine resuscitation techniques in improving fetal oxygen status during labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16132020" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Intrauterine resuscitation during labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8885752" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A prospective randomized trial of two solutions for intrapartum amnioinfusion: effects on fetal electrolytes, osmolality, and acid-base status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35429665" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Acute tocolysis for intrapartum nonreassuring fetal status: how often does it prevent cesarean delivery? A systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9141942" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Intravenous nitroglycerin to relieve intrapartum fetal distress related to uterine hyperactivity: a prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7943823" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Uterine hyperactivity after intrathecal injection of fentanyl for analgesia during labor: a cause of fetal bradycardia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29408586" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A prospective cohort study of fetal heart rate monitoring: deceleration area is predictive of fetal acidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24412117" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Oxygen for intrauterine resuscitation: of unproved benefit and potentially harmful.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33394020" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Maternal Oxygen Supplementation Compared With Room Air for Intrauterine Resuscitation: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32585226" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The effect of intrapartum oxygen supplementation on category II fetal monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15210038" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Sinusoidal heart rate pattern: Reappraisal of its definition and clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/733135" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Sinusoidal fetal heart rate pattern associated with alphaprodine administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29680084" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : No. 197b-Fetal Health Surveillance: Intrapartum Consensus Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16753769" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Fetal acidemia and electronic fetal heart rate patterns: is there evidence of an association?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11776681" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Is intrapartum vibroacoustic stimulation an effective predictor of fetal acidosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7137256" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Fetal heart rate response to scalp blood sampling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12634664" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Intrapartum fetal heart rate patterns in the prediction of neonatal acidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9932571" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Predictive value of electronic fetal monitoring for intrapartum fetal asphyxia with metabolic acidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22939728" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Association and prediction of neonatal acidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1992716" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Neonatal complications at term as related to the degree of umbilical artery acidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17826402" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The intrapartum deceleration in center stage: a physiologic approach to the interpretation of fetal heart rate changes in labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8592523" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Uncertain value of electronic fetal monitoring in predicting cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17826429" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Intrapartum electronic fetal heart rate monitoring and the identification of metabolic acidosis and hypoxic-ischemic encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1172373" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clinical fetal monitoring. VII. The evaluation and significance of intrapartum baseline FHR variability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11776506" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Umbilical artery blood acid-base analysis and fetal heart rate baseline in the second stage of labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11510711" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Computerised analysis of the fetal heart rate and relation to acidaemia at delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3601281" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Second-stage fetal heart rate abnormalities and type of neonatal acidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7246660" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Intrapartum fetal heart rate monitoring. V. Fetal heart rate patterns in the second stage of labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11084540" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A multicenter controlled trial of fetal pulse oximetry in the intrapartum management of nonreassuring fetal heart rate patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19111277" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Measures of acidosis with repetitive umbilical cord occlusions leading to fetal asphyxia in the near-term ovine fetus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17467589" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Intrauterine resuscitation during labor: review of current methods and supportive evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22258939" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Amnioinfusion for potential or suspected umbilical cord compression in labour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8885777" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Amniotic fluid index predicts the relief of variable decelerations after amnioinfusion bolus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7651658" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Comparison of the effects of meperidine and nalbuphine on intrapartum fetal heart rate tracings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10942481" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Fetal response to maternally administered morphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10561630" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The effect of magnesium sulfate on fetal heart rate parameters: A randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7121929" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Antepartum fetal heart rate testing in preterm pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24341" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Development of neurohumoral control of fetal, neonatal, and adult cardiovascular functions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3966014" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Fixed fetal heart rate pattern after intrauterine accidental decerebration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12592266" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Immediate and delayed effects of antenatal corticosteroids on fetal heart rate: a randomized trial that compares betamethasone acetate and phosphate, betamethasone phosphate, and dexamethasone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9386023" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Antenatal corticosteroid therapy and fetal behaviour: a randomised study of the effects of betamethasone and dexamethasone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9692416" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effect of dexamethasone and betamethasone on fetal heart rate variability in preterm labour: a randomised study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10376858" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The effect of betamethasone and dexamethasone on fetal heart rate patterns and biophysical activities. A prospective randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16113556" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effect of betamethasone administration on fetal heart rate tracing: a blinded longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24104779" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Terminal fetal heart decelerations and neonatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21897312" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Frequency of fetal heart rate categories and short-term neonatal outcome.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
